CancerBeone patents new Keap1/CUL3 interaction inducersA recent Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. patent describes new 4-substituted fused bicyclic heteroaryl derivatives acting as Kelch-like ECH-associated protein 1 (Keap1)/CUL3 interaction inducers reported to be useful for the treatment of cancer.